Magnetic Resonance - Technology Information Portal Welcome to MRI Technology
Info
  Sheets

Out-
      side
 



 
 'Bayer HealthCare Pharmaceuticals' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'Bayer HealthCare Pharmaceuticals' found in 1 term [] and 6 definitions [], (+ 1 Boolean[] results
previous     6 - 8 (of 8)     
Result Pages : [1]  [2]
Searchterm 'Bayer HealthCare Pharmaceuticals' was also found in the following services: 
spacer
News  (3)  
 
Magnevist® EnteralInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Magnevist® enteral (Gadopentetate) is a Gd-DTPA solution for use as a gastrointestinal contrast agent to visualize the bowel in MRI scans.

See also Positive Oral Contrast Agents and Gadopentetate Gastrointestinal.
Drug Information and Specification
CENTRAL MOIETY
Gd3+
CONTRAST EFFECT
T1, Predominantly positive enhancement
Paramagnetic
PHARMACOKINETIC
Gastrointestinal
CONCENTRATION
0.001 mol/L
DOSAGE
100 ml oral
PREPARATION
Finished product
INDICATION
Bowel marking
DEVELOPMENT STAGE
For sale
DISTRIBUTOR
See below
PRESENTATION
Vial of 100 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT
STAGE
DISTRIBUTOR
USA
Magnevist® enteral
for sale
EU
Magnevist® enteral
for sale
spacer
Searchterm 'Bayer HealthCare Pharmaceuticals' was also found in the following services: 
spacer
Radiology  (2) Open this link in a new windowUltrasound  (2) Open this link in a new window
Primovist™InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Primovist™ (U.S brand name Eovist®) is a highly specific MRI contrast agent for the imaging, detection and characterization of liver conditions, including liver tumors, cysts, as well as other malignant and benign lesions. It is a water-soluble ethoxybenzyl derivative of Gd-DTPA. This compound is taken up by the hepatocytes (approximately 30% of the dose goes to the hepatocytes) and is equally excreted renal and biliary in humans.
Primovist™ brightens the signal of T1 weighted MR images immediately after contrast administration. Dynamic scanning and imaging of the accumulation phase (best after 20 min.) can also be performed after bolus injection of Primovistâ„¢. The hepatocytes uptake will increase the signal intensity of normal liver parenchyma. This results in improved lesion-to-liver contrast because malignant tumors (metastases, the majority of hepatocellular carcinomas) do not contain either hepatocytes or their functioning is hampered.

WARNING: Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.
Drug Information and Specification
NAME OF COMPOUND
Gadoxetic acid disodium, Gd-EOB-DTPA
CENTRAL MOIETY
Gd2+
CONTRAST EFFECT
T1, Predominantly positive enhancement
Short T1-relaxation time
PHARMACOKINETIC
50% hepatobiliary, 50% renal excretion
884 mosm/kgH2O
CONCENTRATION
0.25 mol/L
DOSAGE
12,5 - 25 µmol/kg
PREPARATION
Finished product
INDICATION
Liver lesions
DEVELOPMENT STAGE
for sale
DISTRIBUTOR
See below
PRESENTATION
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT
STAGE
DISTRIBUTOR
EU
Primovist™
for sale
spacer

• View the DATABASE results for 'Primovist™' (7).Open this link in a new window

 
Further Reading:
  Basics:
New MRI liver contrast agent Primovist® approved in EU
Thursday, 30 September 2004   by www.secinfo.com    
New MRI Liver Contrast Medium
Wednesday, 13 October 2004   by www.hospimedica.com    
Important Drug Warning for Gadolinium-Based Contrast Agents
Wednesday, 12 September 2007   by www.ismrm.org    
MAGNETIC RESONANCE IMAGING OF FOCAL LIVER LESIONS(.pdf)
2002
  News & More:
Comparison of liver scintigraphy and the liver-spleen contrast in Gd-EOB-DTPA-enhanced MRI on liver function tests
Thursday, 18 November 2021   by www.nature.com    
EMA's final opinion confirms restrictions on use of linear gadolinium agents in body scans
Friday, 21 July 2017   by www.ema.europa.eu    
FDA Drug Safety Communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings
Tuesday, 19 December 2017   by www.fda.gov    
Gadolinium-containing contrast agents: removal of Omniscan and iv Magnevist, restrictions to the use of other linear agents
Friday, 5 January 2018   by www.gov.uk    
MRI Resources 
Process Analysis - Software - Movies - Portals - Developers - Liver Imaging
 
EPIX Pharmaceuticals, Inc.MRI Resource Directory:
 - Developers -
 
www.epixmed.com [This entry is marked for removal.]

(July 20, 2009 - EPIX Pharmaceuticals, Inc. announced today that, in light of the company's lack of capital and inability to obtain additional financing or consummate a strategic transaction, it has entered into an Assignment for the Benefit of Creditors, effective immediately, in accordance with Massachusetts law).
EPIX has been a specialty pharmaceutical firm developing targeted contrast agents to improve the capability of MRI as a diagnostic tool for a variety of diseases. Gadofosveset trisodium (formerly MS-325, Vasovist™, now ABLAVARt™), is an injectable intravascular contrast agents designed for multiple vascular imaging applications, including peripheral vascular disease and coronary artery disease. EPIX conducted a pivotal Phase III trial for the detection of peripheral vascular disease, as well as a Phase II feasibility trial for coronary artery disease diagnosis.
To ensure rapid development and adoption of gadofosveset trisodium into clinical practice upon regulatory approval, EPIX pursued an aggressive product development plan and commercialization strategy. The Company established an exclusive, worldwide sales and marketing agreement with Bayer Schering Pharma AG. EPIX also established corporate collaborations with GE Healthcare, Philips Medical Systems and Siemens Medical Systems, the three leading MRI manufacturers, which together account for approximately 80 percent of the MRI machines installed worldwide.
EPIX had other MRI contrast agents under development, most significantly a novel prototype blood clot agent (EP-2104R). Potential clinical applications for this type of agent include detection of deep venous thrombosis, pulmonary embolism and blood clots in the coronary and carotid arteries. Currently, there is no high resolution imaging technique to directly visualize blood clots in patients with suspected cardiovascular disease.
spacer

• View the DATABASE results for 'EPIX Pharmaceuticals, Inc.' (7).Open this link in a new window


• View the NEWS results for 'EPIX Pharmaceuticals, Inc.' (69).Open this link in a new window.
 
Further Reading:
  Basics:
Epix Pharmaceuticals to shut down
Tuesday, 21 July 2009   by boston.bizjournals.com    
Searchterm 'Bayer HealthCare Pharmaceuticals' was also found in the following services: 
spacer
News  (3)  
 
previous      6 - 8 (of 8)     
Result Pages : [1]  [2]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?    



New acceleration techniques will :
reduce scan times 
cause artifacts 
increase expenses 
be useful if you have a lot of experience 
doesn't do much 
never heard of 

Look
      Ups





MR-TIP.com uses cookies! By browsing MR-TIP.com, you agree to our use of cookies.

Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • Medical-Ultrasound-Imaging • 
Copyright © 2003 - 2024 SoftWays. All rights reserved. [ 27 April 2024]
Terms of Use | Privacy Policy | Advertising
 [last update: 2024-02-26 03:41:00]